Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2026 07:32 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Register now for free and join on June 10, 2026 Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech...
June 04, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
June 04, 2026 07:00 ET | Source: GH Research PLC

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance...
June 03, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
June 03, 2026 06:05 ET | Source: MannKind

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
May 30, 2026 14:30 ET | Source: Orion Oyj

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid...
May 30, 2026 14:30 ET | Source: Orion Oyj

Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia ja edennyt syöpä

ORION OYJ LEHDISTÖTIEDOTE 30.5.2026 KLO 21.30 Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla...
May 29, 2026 12:30 ET | Source: MannKind

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
May 28, 2026 17:29 ET | Source: Taurus Medical, Inc

Taurus Meds TRT Claims Evaluated: Powerful Testosterone Replacement Therapy & Taurus Charge ED Medication

Taurus Meds online TRT claims and Taurus Charge 4-in-1 ED evaluated: $49 intake, $149/mo TRT, $129.90 sublingual ED, clinician-prescribed.
May 28, 2026 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Upcoming Investor Conference Presentations

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver...